PEAK ATP® (Disodium Adenosine Triphosphate)

Evidence Level
Strong
2 Clinical Trials
4 Documented Benefits
4/5 Evidence Score

PEAK ATP® (TSI Group) is a patented, clinically validated form of adenosine 5'-triphosphate disodium — the only nutritional ingredient structurally identical to the ATP produced and used by the human body. Unlike supplements that support ATP production indirectly (creatine, CoQ10, D-ribose), PEAK ATP® provides ATP directly as a signaling molecule that improves blood flow, muscle excitability, and fatigue resistance through extracellular purinergic receptor activation. Multiple human RCTs confirm improvements in strength, lean body mass, muscle thickness, and fatigue resistance at 400 mg/day.

Studied Dose 400 mg/day PEAK ATP® (disodium ATP); acute: 400 mg taken 30–60 minutes pre-exercise; chronic: 400 mg/day continuously for 12 weeks (demonstrated safe and effective in RCTs)
Active Compound Adenosine 5'-triphosphate disodium (ATP) — PEAK ATP® by TSI Group Co., Ltd.; patented bioavailable disodium ATP form; 400 mg/day clinically validated dose

Strength and lean body mass gains

A 12-week double-blind RCT in resistance-trained men demonstrated PEAK ATP® (400 mg/day) combined with resistance training significantly increased muscle thickness, lean body mass, and total body strength vs. placebo + training. A meta-analysis of 5 RCTs confirmed significant improvements in maximal strength with ATP supplementation vs. placebo, particularly in resistance-trained men.

Fatigue resistance and endurance maintenance

Acute PEAK ATP® supplementation (400 mg) significantly improved maintenance of peak force output during repeated high-intensity sets — reducing fatigue rate and preserving peak torque in later sets of exhaustive exercise. This anti-fatigue mechanism is distinct from energy production support (creatine) and works through improved blood flow and reduced muscle fatigue signaling.

Blood flow and muscle vasodilation

Extracellular ATP activates P2Y purinergic receptors on endothelial cells, triggering nitric oxide and prostaglandin release that drives vasodilation in active muscle. This blood flow enhancement improves oxygen and nutrient delivery to working muscle — complementary to NO-boosting ingredients like L-citrulline but through a completely different mechanism.

Amino acid absorption enhancement

New 2025 research confirms oral PEAK ATP® significantly enhances amino acid bioavailability following protein consumption in both younger and older adults. ATP's role in intestinal amino acid transport (stimulating P2Y receptors on enterocytes to enhance amino acid uptake) creates a novel application as a protein-potentiating ingredient in protein powders and recovery formulas.

1

Extracellular purinergic receptor signaling

Orally consumed ATP is not primarily absorbed intact into circulation — instead, it acts as an extracellular signaling molecule in the gut and vasculature by activating P2X and P2Y purinergic receptors on intestinal epithelium, endothelial cells, and red blood cells. P2Y receptor activation triggers NO-mediated vasodilation, P2X activation enhances muscle calcium release for stronger contractions, and intestinal P2Y signaling enhances amino acid transporter activity. This extracellular signaling mechanism explains ATP's efficacy despite limited systemic absorption.

1
PEAK ATP® and Muscle Mass, Strength, Recovery — 12-Week RCT
PubMed

Randomized, double-blind, placebo-controlled trial of PEAK ATP® (400 mg/day) + resistance training vs. placebo + training in resistance-trained men for 12 weeks. Published in Journal of the International Society of Sports Nutrition.

Resistance-trained men. 12-week training + supplementation RCT.

PEAK ATP® significantly increased muscle thickness (+1.7 cm quad), lean body mass (+1.7 kg), vertical jump power (+30%), and total body strength vs. placebo group. Blood flow and muscle excitability markers improved. No adverse effects at 400 mg/day for 12 weeks.

2
ATP Supplementation Meta-Analysis — Strength and Power
PubMed

Systematic review and meta-analysis of 5 human clinical studies (2000–2022) examining oral ATP supplementation effects on maximal strength.

5 RCTs, resistance-trained and recreationally active adults.

ATP supplementation produced significant improvements in maximal strength vs. placebo across all 5 studies. Effect concentrated in resistance-trained men. 400 mg/day for up to 12 weeks deemed safe. Supports PEAK ATP® as evidence-based strength and performance ingredient.

Common Potential side effects

Well tolerated at 400 mg/day in all clinical studies up to 12 weeks
No significant adverse events reported across all published RCTs
High-purine content — relevant for gout sufferers; consult physician

Important Drug interactions

Antiplatelet/anticoagulant medications — ATP activates platelet P2Y receptors; theoretical additive antiplatelet effect
Dipyridamole — inhibits adenosine metabolism; may potentiate ATP effects; consult physician
No clinically significant pharmacokinetic drug interactions at 400 mg/day